熱門資訊> 正文
4DT在4D-150湿AMD开发日强调4D-150的临床活动和4FRONT第3阶段项目的设计
2024-09-19 04:07
- 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data
- In broad population (Phase 2b), 70% injection-free through 52 weeks
- In severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks
- 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved anti-VEGF agents
- 4FRONT Phase 3 program designed to maximize 4D-150's potential, including probabilities of clinical, regulatory and commercial success across global markets
- Corporate webcast to be held on September 18, 2024 at 4:15 p.m. ET
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
